Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 26 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a licensing and commercialization agreement with RK Pharma for a novel oncology supportive care product intended for the US market. Under this agreement, RK Pharma will manufacture the product while Zydus will handle the NDA submission and commercialization. The product aims to reduce dosing errors and enhance compliance among healthcare professionals. This partnership reflects Zydus's commitment to delivering high-quality medicines and improving patient care in the US.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 26, 2025, titled "Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases